Soluble Guanylate Cyclase (sGC or EC 188.8.131.52) - Pipeline Review, H1 2018
Soluble Guanylate Cyclase (sGC or EC 184.108.40.206) pipeline Target constitutes close to 27 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The latest report Soluble Guanylate Cyclase - Pipeline Review, H1 2018, outlays comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 220.127.116.11) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Soluble Guanylate Cyclase (sGC or EC 18.104.22.168) - Soluble guanylyl cyclase (sGC) is the known receptor for nitric oxide. Binding of nitric oxide to the heme moiety of the cyclase induces its capacity to synthesize the second messenger cGMP. Although the changes in the state of the heme moiety upon exposure of enzyme to NO and its correlation to the stimulation of sGC catalytic activity.
The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 3, 13 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Report covers products from therapy areas Cardiovascular, Metabolic Disorders, Ophthalmology, Central Nervous System, Gastrointestinal, Hematological Disorders, Immunology, Infectious Disease, Oncology, Respiratory, Dermatology, Genetic Disorders, Genito Urinary System And Sex Hormones and Toxicology which include indications Ocular Hypertension, Glaucoma, Diabetic Nephropathy, Pulmonary Hypertension, Sickle Cell Disease, Tinea pedis (Athlete Foot), Acute Respiratory Distress Syndrome, Alzheimer's Disease, Carotid Artery Stenosis, Chemotherapy Induced Peripheral Neuropathy, Chronic Kidney Disease (Chronic Renal Failure), Cystic Fibrosis, Diabetic Foot Ulcers, Diabetic Neuropathic Pain, Diastolic Heart Failure, Duchenne Muscular Dystrophy, Esophageal Achalasia, Hypertension, Inflammation, Ischemic Stroke, Liver Diseases, Lung Infections, Onychomycosis (Tinea Unguium), Open-Angle Glaucoma, Optic Neuropathy, Osteoporosis, Pancreatic Cancer, Prostate Cancer, Pulmonary Arterial Hypertension, Stroke, Systemic Sclerosis (Scleroderma), Systolic Heart Failure, Vascular Dementias and Wounds.
Furthermore, this report also reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 22.214.171.124) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook